This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Kurata et al.1 report successful treatment of a patient with subacute sclerosing panencephalitis (SSPE) by intrathecal α-interferon (IFN) administered via an implantable subcutaneous reservoir attached to an indwelling spinal catheter. Based on our experience,2,3 we agree that continuous intraventricular IFN treatment via an Ommaya reservoir is risky and cumbersome. We therefore applied continuous intrathecal infusion pump systems (i.e., the type used for intrathecal administration of baclophen or opiates) to overcome the risk of infection in two SSPE patients.
In the first patient, who was treated between 1989 and 1991,3 residual drug was withdrawn from the pump at various intervals and tested for IFN activity. We found that for up to 3-week intervals, the drug activity does not deteriorate so the pump was loaded once every …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Costs and Utilization of New-to-Market Neurologic Medications
Dr. Robert J. Fox and Dr. Mandy Leonard
► Watch
Alert Me
Recommended articles
Measles virus–specific plasma cells are prominent in subacute sclerosing panencephalitis CSF
Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis
Pearls & Oy-sters: Pisa syndrome
Functional MxA promoter polymorphism associated with subacute sclerosing panencephalitis